After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...